129 related articles for article (PubMed ID: 38598369)
21. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma.
Jiang C; Long J; Liu B; Xu M; Wang W; Xie X; Wang X; Kuang M
J Exp Clin Cancer Res; 2017 Jul; 36(1):99. PubMed ID: 28750679
[TBL] [Abstract][Full Text] [Related]
22. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
23. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
[TBL] [Abstract][Full Text] [Related]
24. Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3.
Suo Y; Du D; Chen C; Zhu H; Wang X; Song N; Lu D; Yang Y; Li J; Wang J; Luo Z; Zhou B; Luo C; Zhou H
J Med Chem; 2024 Mar; 67(6):4804-4818. PubMed ID: 38466231
[TBL] [Abstract][Full Text] [Related]
25. PROTACs: A novel strategy for cancer drug discovery and development.
Han X; Sun Y
MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
[TBL] [Abstract][Full Text] [Related]
26. Polyphyllin VII as a Potential Drug for Targeting Stemness in Hepatocellular Cancer
Xu L; Chen Z; Wang Y; Li Y; Wang Z; Li F; Xi X
Curr Cancer Drug Targets; 2023; 23(4):325-331. PubMed ID: 36284387
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer.
Li H; Wang L; Cao F; Yu D; Yang J; Yu X; Dong J; Qin JJ; Guan X
Front Pharmacol; 2022; 13():944455. PubMed ID: 36034876
[TBL] [Abstract][Full Text] [Related]
28. E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities.
Zou Q; Liu M; Liu K; Zhang Y; North BJ; Wang B
Cell Oncol (Dordr); 2023 Jun; 46(3):545-570. PubMed ID: 36745329
[TBL] [Abstract][Full Text] [Related]
29. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma.
Lee C; Cheung ST
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731457
[TBL] [Abstract][Full Text] [Related]
30. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression.
Bhummaphan N; Petpiroon N; Prakhongcheep O; Sritularak B; Chanvorachote P
Phytomedicine; 2019 Sep; 62():152932. PubMed ID: 31100681
[TBL] [Abstract][Full Text] [Related]
31. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog.
Cao J; Zhao M; Liu J; Zhang X; Pei Y; Wang J; Yang X; Shen B; Zhang J
Theranostics; 2019; 9(3):811-828. PubMed ID: 30809310
[TBL] [Abstract][Full Text] [Related]
32. The Natural Pigment Violacein Potentially Suppresses the Proliferation and Stemness of Hepatocellular Carcinoma Cells In Vitro.
Kim YJ; Yuk N; Shin HJ; Jung HJ
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639072
[TBL] [Abstract][Full Text] [Related]
33. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.
Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW
Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991
[TBL] [Abstract][Full Text] [Related]
34. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
Yu S; Wang Y; Lv K; Hou J; Li W; Wang X; Guo H; Wang W
Technol Cancer Res Treat; 2021; 20():15330338211027916. PubMed ID: 34238066
[TBL] [Abstract][Full Text] [Related]
35. STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC.
Ghoshal S; Fuchs BC; Tanabe KK
Hepatobiliary Surg Nutr; 2016 Jun; 5(3):201-3. PubMed ID: 27275460
[TBL] [Abstract][Full Text] [Related]
36. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
37. A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase.
Peng T; Wonganan O; Zhang Z; Yu J; Xi R; Cao Y; Suksamrarn A; Zhang G; Wang F
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805945
[TBL] [Abstract][Full Text] [Related]
38. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.
Xu J; Lin H; Wu G; Zhu M; Li M
Front Oncol; 2021; 11():760971. PubMed ID: 34976809
[TBL] [Abstract][Full Text] [Related]
39. Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells.
Shi C; Yang J; Hu L; Liao B; Qiao L; Shen W; Xie F; Zhu G
Aging (Albany NY); 2020 Aug; 12(15):15546-15555. PubMed ID: 32756004
[TBL] [Abstract][Full Text] [Related]
40. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
